Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Drug maker Eli Lilly says data from a late-stage trial showed a reduction in weight of almost 8% in people with Type 2 ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.